Cancer clinical trials in the region Auvergne-Rhône-Alpes
509 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819007
#2024-516982-35-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Mucinous carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded genetic anomalies
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3
Kidney cancer
#NCT07489495
#2024-516993-31-00
Required histologic types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Thyroid and adrenal gland cancer
#NCT04290663
#2024-514603-34-00
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3
Thyroid and adrenal gland cancer
#NCT03583710
Required histologic types
Adrenal gland cancer
Required histologic sub types
Adrenocortical carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
Mitotane
10 recruiting sites
M.D. Anderson Cancer Center
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Head and neck cancer
#NCT06496178
#2023-510322-32-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
15 recruiting sites
Merus
Phase 3
Head and neck cancer
#NCT06129864
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Radiochemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Surgery
Radiotherapy
8 recruiting sites
AstraZeneca
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
16 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
16 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Breast cancer
#NCT05512364
#2022-501453-36-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Surgery
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer